A GOP congresswoman is touting recently released Food and Drug Administration (FDA) guidance on psychedelics research and calling for additional work to study the therapeutic benefits of marijuana for military veterans.
In a speech on the House floor on Wednesday, Rep. Mariannette Miller-Meeks (R-IA) talked about the need to support “novel forms of research” to unlock the potential of psychedelics and cannabis for the treatment of conditions like post-traumatic stress disorder (PTSD) that commonly afflict veterans.
“As a doctor, former director of the Iowa Department of Public Health and 24-year U.S. Army veteran, the mental, emotional and physical health of my constituents and fellow veterans is one of my top priorities in Congress,” she said. “For too long, PTSD and other mental or physical ailments have had devastating effects and far too often go untreated.”
“The new FDA guidance that presents considerations for designing clinical trials for psychedelic drugs will give patients and their doctors increased access to effective treatments, rather than alternatives such as opioids,” she said.
The guidance was also requested under a bipartisan bill that Miller-Meeks introduced, alongside Reps. Dan Crenshaw (R-TX) and Ro Khanna (D-CA), late last month. Days after that filing, FDA came out with
Read full article on Marijuana Moment
